IWAA 2019 22nd Annual Scientific Session

Coeur d'Alene, ID US
July 25, 2019 to July 27, 2019

This program is designed to allow learners to continue exploring the immunology frontier.

This activity is supported by independent educational grants from Sanofi and Stallergenes Greer

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Intermountain West Allergy Association (IWAA).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of  13 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Summarize recent data, expert opinion and clinical practice guidelines on the treatment of allergic and immunological disease
  2. Describe the safety and efficacy profiles of established and emerging therapies for the treatment of allergic and immunological diseases
  3. Apply knowledge of the pathophysiology of allergic and immunological diseases to clinical decision making.
     
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Terri Brown-Whitehorn, MD (Speaker) – Consultant – DBV Technologies; Contract Research – DBV Technologies
Warner Carr, MD (Speaker): Consultant - AstraZeneca, Regeneron, Sanofi, Teva; Speaker – AstraZeneca, Regeneron, Sanofi, Teva
Richard Henry, MD (Moderator): Principal Investigator – Avillion, Genentech, Roche, Teva
Bradley E. Chipps, MD (Speaker): Advisory Board – AstraZeneca, Circassia ,Genentech ,Novartis, Regeneron, Sanofi, Teva; Speaker – AstraZeneca, Circassia, Genentech, Novartis, Regeneron, Sanofi, Teva
David Khan, MD (Speaker): Consulting Fee – Aimmune

Kenneth Paris, MD (Speaker): Advisory Board – Grifols, Shire/Takeda; Speaker – Shire/Takeda

Mike Tankersley, MD (Speaker): Advisory Board -ALK; Speaker – ALK

James M. Tracy, Do (Speaker): Advisory Board - Pharming

Carl Thornblade, MD (Moderator): Advisory Board – Pharming; Contracted Research - AstraZeneca, Chiesi, Genentech, Leo Pharma, Novartis, Romark, Teva, VBI Vaccines, West-Ward

The following have no relevant financial relationships to disclose:Jeffrey G. Demain, MD (Speaker)
Ronald England, MD (Moderator)
Jim Thompson, PhD (Speaker)
Greg Wickern, MD (Moderator)
Doug Huneywell (Meeting Planner)

Course summary
Available credit: 
  • 13.00 AMA PRA Category 1 Credit™
  • 13.00 Attendance
Course opens: 
07/25/2019
Course expires: 
07/27/2021
Event starts: 
07/25/2019 - 4:30pm
Event ends: 
07/27/2019 - 5:00pm
Cost:
$0.00
Rating: 
0
Coeur d'Alene
115 S. 2nd Street
Coeur d'Alene, ID 83814
United States
+1 (855) 703-4648

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Intermountain West Allergy Association (IWAA).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of  13 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Available Credit

  • 13.00 AMA PRA Category 1 Credit™
  • 13.00 Attendance

Accreditation Period

Course opens: 
07/25/2019
Course expires: 
07/27/2021

Price

Cost:
$0.00
Please login or create an account to take this course.